Anna Kan
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 10%
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
Papers in
- Hepatology 21
- Hepatocellular Carcinoma Treatment and Prognosis 21
- Oncology 11
- Cancer Immunotherapy and Biomarkers 9
- Cancer-related Molecular Pathways 1
- Pancreatic and Hepatic Oncology Research 1
- Co-authors
- Ming Shi (20 shared papers)Rong Guo (12 shared papers)Minke He (14 shared papers)Wei Wei (9 shared papers)QiJiong Li (11 shared papers)ZhiCheng Lai (14 shared papers)Haijing Deng (3 shared papers)Zhenfeng Zhang (2 shared papers)
In The Last Decade
Anna Kan
34 papers receiving 1k citations
Peers
Comparison fields: 5 of 60
- Hepatology 435
- Cancer Research 171
- Oncology 220
- Immunology 77
- Molecular Biology 169
Countries citing papers authored by Anna Kan
This map shows the geographic impact of Anna Kan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Kan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Kan more than expected).
Fields of papers citing papers by Anna Kan
This network shows the impact of papers produced by Anna Kan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Kan. The network helps show where Anna Kan may publish in the future.
Co-authors
The 25 scholars most cited alongside Anna Kan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 156 | |
| 2 | 2020 | 143 | |
| 3 | 2022 | 130 | |
| 4 | 2020 | 66 | |
| 5 | 2019 | 53 | |
| 6 | 2021 | 52 | |
| 7 | 2019 | 38 | |
| 8 | 2020 | 35 | |
| 9 | 2019 | 33 | |
| 10 | 2021 | 30 | |
| 11 | 2022 | 25 | |
| 12 | 2019 | 24 | |
| 13 | 2019 | 23 | |
| 14 | 2022 | 19 | |
| 15 | 2023 | 19 | |
| 16 | 2018 | 17 | |
| 17 | 2020 | 16 | |
| 18 | 2018 | 15 | |
| 19 | 2019 | 15 | |
| 20 | 2021 | 15 |
About Anna Kan
Anna Kan is a scholar working on Hepatology, Oncology, Cancer Research, Immunology and Epidemiology, having authored 36 papers that have together received 1k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (21 papers), Cancer Immunotherapy and Biomarkers (9 papers), Cancer-related molecular mechanisms research (5 papers), Immune cells in cancer (2 papers), Hepatitis B Virus Studies (2 papers), Epigenetics and DNA Methylation (1 paper), Cancer-related Molecular Pathways (1 paper) and Pancreatic and Hepatic Oncology Research (1 paper). The work is most often cited by research in Hepatology (435 citations), Cancer Research (171 citations), Oncology (220 citations), Immunology (77 citations) and Molecular Biology (169 citations). Anna Kan has collaborated with scholars based in China and Hong Kong. Frequent co-authors include Ming Shi, Rong Guo, Minke He, Wei Wei, QiJiong Li, ZhiCheng Lai, Haijing Deng, Zhenfeng Zhang, Ming Dan Zhao and Ning Lyu. Their work appears in journals such as Cancer Cell International, Journal of Cancer, Cell Death and Disease, Cancer Medicine and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.